Prevalence of Factor V Leiden G1691A,MTHFR C677T,and Prothrombin G20210A Among Asian Indian Sickle Cell Patients

Abstract

The prevalence of factor V (FV) Leiden G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations were investigated among 90 sickle trait, 61 sickle homozygous, 75 sickle beta thalassemia, and 15 HbSD Asian Indian sickle cell patients. In all, 297 healthy controls were evaluated to compare the polymorphism frequency. The prevalence of FV Leiden heterozygous G>A were significant in the group (P = .02), while PRT G20210A polymorphism was not seen among patients as well as controls. However, an increased frequency of the MTHFR 677 C>T genotype was seen among patients as well as controls, but this was not statistically significant (P = .13). This suggested a low impact of inherited hypercoagulability risk factors in the pathogenesis of sickle cell disease and/or its complications.

Keywords

SCD polymorphism factor V Leiden MTHFR prothrombin

Introduction

Sickle cell disease (SCD) is one of the most common inherited diseases in the world. In India, 10 000 individuals with SCD are reported per million populations. Even with the same inherited DNA mutation within the β-globin gene, patients present a notorious clinical heterogeneity.¹ Additional genetic factors such as α-thalassemia, fetal hemoglobin synthesis, and β-globin haplotype have been identified, but none of these can fully explain the differences in clinical expression observed in these patients. Probably, there are other elements that contribute to the many phenotypes of the disease.^2–5 It has been known for a long time that patients with SCD show activation of the blood coagulation and fibrinolytic systems, as well as increased platelet activity and consumption of coagulation inhibitors, especially during vaso-occlusive crises and also during the steady state of the disease.^6–9 Vascular complications are an important and perplexing aspect of the clinical spectrum of sickle cell anemia, although there is controversial evidence surrounding the role of thrombosis in this complication.^10,11 Because of the importance of vascular complications in the pathophysiology of SCD, a number of genetic polymorphisms associated with thrombophilia have been studied as potential genetic modifiers of SCD. Inherited risk factors for vascular disease include factor V (FV) Leiden (G1691A),¹² prothrombin (PRT) G20210A,¹³ and methylenetetrahydrofolate reductase (MTHFR) C677T point mutations¹⁴; and in view of their role in enhancing thrombus formation, it was suggested that these mutations play a role in the pathogenesis of SCD^15,16 and/or its complications. It has been hypothesized that this subset may have some other underlying genetic predisposition. A possible pathogenetic mechanism is thrombophilia. Glueck et al¹⁷ found that 74% of their patients (none of whom had SCD) with osteonecrosis had one or more primary coagulation disorders, the most common of which were resistance to activated protein C (APC) and hypofibrinolysis or a combination of both. Hyperhomocysteinemia, which can result from a variety of enzymatic defects in the biochemical pathway of folate metabolism, is an independent risk factor for premature vascular disease.^18–20 A C>T substitution at nucleotide 677 in the MTHFR gene is associated with a thermolabile phenotype and diminished enzyme activity with consequent hyperhomocysteinemia. Studies among patients with SCD from Brazil¹⁶ and the United States^15,21 have not demonstrated an association with ischemic stroke; however, Kutlar et al²² identified this MTHFR mutation as a risk factor in the development of avascular necrosis (AVN) among their patients. No authentic data have been reported among Asian Indians. In this study, the prevalence of these 3 point mutations was assessed in patients with SCD and healthy controls from Asian Indian origin.

Materials and Methods

Study participants were 241 sickle cell patients and 297 age- and sex-matched controls and all were Indians. Five milliliters of venous blood were collected after obtaining the signed informed consent form. Study was approved by the institutional ethic committee. All sickle subtype was diagnosed by cation exchange high-performance liquid chromotography, and complete blood count analysis was done by Sysmex auto analyzer.

Detection of Polymorphism

Total genomic DNA was isolated from peripheral blood leukocytes by the kit (bioserve) method. Factor V Leiden, PRTG20210A, and MTHFR C677T genotype analysis was performed by polymerase chain reaction–restriction fragment length polymorphism analysis using MnlI 12, HindIII 13, and HinfI 14 digestion (all procured from New England Biolabs, Beverly, Massachusetts). Statistical analysis was performed using GraphPad statistics software. Yates chi-square test was used to assess the intergroup significance.

Result

The study participants were divided into 5 groups; group 1 comprised 90 sickle trait (52 male and 38 female with a mean age of 22.27 ± 4.11), group 2 comprised 61 sickle homozygous (36 male and 25 female with a mean age of 11.38 ± 7.62), group 3 comprised 75 sickle beta thalassemia (57 male and 18 female with a mean age of 12 ± 8.33), group 4 comprised 15 sickle D (10 male and 5 female with a mean age of 6.53 ± 4.35), and group 5 comprised 297 controls (175 male and 122 female with a mean age of 11.36 ± 7.718).

Among the sickle traits, 3 were heterozygous (G>A) and none was a homozygous (A>A) carrier of FV Leiden; while in sickle homozygous patients, 4 were heterozygous and 1 was homozygous. Among patients with sickle beta thalassemia, 8 were heterozygous and 1 was homozygous; while in sickle D patients, 2 were heterozygous and 1 was homozygous. Higher frequency of FV Leiden gene was found in sickle D patients (20%) while among controls, 73 were heterozygous and 27 were homozygous carrier.

Eleven heterozygous of MTHFR C677T found in sickle trait, while 13 heterozygous and 4 homozygous in HbSS (Sickle cell anemia) patients. In patients with sickle beta thalassemia, 16 were heterozygous and 4 homozygous; while, in contrast, in patients with sickle D, 2 were heterozygous, a significant increase in MTHFR C677T carrier rate (27.6%) was seen in sickle homozygous patients compared to healthy participants where 37 were heterozygous and 3 were homozygous (13.5%). No frequency of heterozygous PRT G20210A was found in any of the patient groups and controls. However, the frequency of the FV Leiden (G1691A) and MTHFR (C677T) point mutations was higher among patients when compared to controls, but this did not reach statistical significance. All the details are given in Table 1 .

Table 1.

Frequency of thrombotic mutations in sickle cell patients

		Patients
		SA	SS	Sβ	SD
Mutation	Genotype	N = 90	N = 61	N = 75	N = 15	Control N = 297	P Value	OR	95% CI
FV Leiden	G>G	87 (96.7)	56 (91.8)	66 (88.0)	12 (80.0)	289 (97.3)	.006	0.31	0.12-0.75
	G>A	3 (3.3)	4 (6.6)	8 (10.7)	2 (13.3)	8 (2.7)	.029	2.74	1.09-7.06
	A>A	0 (0)	1 (1.6)	1 (1.3)	1 (6.7)	0	.16	NA	NA
MTHFR	C>C	79 (87.8)	44 (72.1)	55 (73.3)	13 (86.7)	257 (86.5)	.032	0.59	0.37-0.96
	C>T	11 (12.2)	13 (21.3)	16 (21.3)	2 (13.3)	37 (12.5)	.134	1.48	0.89-2.46
	T>T	0 (0)	4 (6.6)	4 (5.3)	0 (0)	3 (1.0)	.11	3.36	0.8-16.17
PRT	G>G	90 (100)	61 (100)	75 (100)	15 (100)	297 (100)	NA	NA	NA
	G>A	0	0	0	0	0
	A>A	0	0	0	0	0

Abbreviations: FV, factor V; MTHFR, methylenetetrahydrofolate reductase; PRT, prothrombin; OR, odds ratio; CI, confidence interval; SA, Sickle Trait; SS, Sickle Homozygous; Sβ, Sickle β-thlassemia; SD, Sickle Hemoglobin D.

Discussion

Several genetic factors contribute to the phenotypic diversity of SCD, and genetic polymorphisms associated with thrombophilia were implicated as genetic modifiers of SCD.¹⁵ The importance of thrombosis in the pathophysiology of SCD has been recently recognized. Insofar as FV Leiden, PRT G20210A, and MTHFR C677T were implicated in the pathogenesis of thrombotic events, we assessed their prevalence among patients with SCD. Low frequencies of FV Leiden (1.90%) and PRT G20210A (0.0%) were seen among healthy individuals in Eastern Saudi Arabia (Dammam),²³ in agreement with a study on their prevalence in Western Saudi Arabia (Jeddah), where rates of 2.2% and 1.1% were reported for FV Leiden and PRT G20210A, respectively.²⁴ Considerable evidence suggests that endothelial damage and thrombosis play important contributory roles in the vaso-occlusive complications of SCD.^10,25 Among all the groups, 3 patients with HbS were homozygous FV Leiden and 17 patients with sickle cell were heterozygous FV Leiden, and 8 in control group were heterozygous FV Leiden . Heterozygous FV Leiden frequency was statistically significant (P = .02). Prothrombin (PRT G20210A) polymorphism was not detected in any group of patients and controls. MTHFR C677T appears to play a role in SCD, evidenced by increased prevalence of T>T (and C>T) genotypes among patients with SCD. The MTHFR 677TT genotype was detected in 3.31% of HbS patient group while 1.22% among controls; 17.42% of heterozygous MTHFR 677C>T (17.42%) was detected in sickle patient group and 15.35% in the controls. Although MTHFR 677T gene frequency is high in patients and controls, this did not reach statistical significant level. Other investigator reported the prevalence^15,26–28 in the range of 1% to 2.8%. Balasa et al²⁷ found a prevalence of 1% for this genotype among 110 normal American Blacks, whereas its prevalence among Caucasians ranges from 10% to 20%, depending on the geographic distribution.^29–34 In Brazil, despite the great miscegenation, there seems to be a high proportion of Caucasians within normal individuals, and Morelli et al³⁵ reported a 9% prevalence of 677TT and Franco et al³⁶ found a 16.6% prevalence. Some investigators did not find an association between MTHFR C677T and clinical manifestations in SCD. According to the previous reports, FV Leiden and PRT gene mutations were found at a high frequency in some European regions and were very rare in African descendents. In Brazil, reports have described a low frequency in the general population, varying from 1% to 2% and 0.7% to 3.6% for the G1691A and G20210A mutations, respectively. The frequency of the 677TT allele (MTHFR) in Brazil is high among Caucasians (10.3%) but low in African descendents (1.4%) and Indians (1.2%). On the other hand, reports from the State of São Paulo presented very different results for the frequency of the 677TT allele in patients with SCD, with none in Campinas and 1.8% in São Paulo.^16,37,38 In French Canadians,¹⁹ it has been reported as 38%while in a Brazilian study, it was found to be 36% in whites, 40% in Asians, 24% in Amerindians, 5% in African Blacks, and 12% in Brazilian Blacks.³⁹ Two studies among African American patients with SCD reported frequencies of 9% and 15%, respectively.^16,22

Conclusion

In conclusion, our data suggest a low impact of inherited hypercoagulability risk factors in the pathogenesis of SCD and/or its complications. Sickle cell disease is generally mild among patients probably because the patients carry the Saudi Arabia/India bS-globin gene cluster haplotype that is associated with a high Hb F level. Both thrombosis and the sickle cell anemia have contradict pathophysiology that makes a mild phenotype of the disease.

Footnotes

Acknowledgments

The authors thank the technical staff of the Department of Hematology, AIIMS, for expert assistance.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: supported by ICMR & Hematology Department AIIMS, New Delhi, India.

References

Serjeant

GR.

The case for dedicated sickle cell centres. Indian J Hum Genet. 2006;12(3):148–151.

Steinberg

Rosenstock

Coleman

. sickle cell anemia. Blood. 1984;63(6):1353–1360.

Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of Powards DR. ßs Gene cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am. 1991;5(3):475–493.

Rieder

Safaya

Gillette

. Effect of beta-globin gene cluster haplotype on the hematological and clinical features of sickle cell anemia. Am J Hematol. 1991;36(3):184–189.

Figueiredo

Kerbauy

Goncalves

. Effect of alpha-thalassemia and beta-globin gene cluster haplotypes on the hematological and clinical features of sickle-cell anemia in Brazil. Am J Hematol. 1996;53(2):72–76.

Lourenço

Sampaio

Kerbauy

Sampaio

CA.

Estimation of plasma kallikrein in sickle-cell anemia, and its relation to the coagulation and fibrinolytic systems. Adv Exp Med Biol. 1989;247B:553–557.

Peters

Plaat

ten Cate

Wolters

Weening

Brandjes

DP.

Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost. 1994;71(2):169–172.

Key

Slungaard

Dandelet

. Whole blood tissue factor procoagulant activity is elevated inpatients with sickle cell disease. Blood. 1998;91(11):4216–4223.

Bayazit

Kilinc

Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int. 2001;43(6):592–596.

10.

Setty

Rao

Stuart

MJ.

Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001;98(12):3228–3233.

11.

Hebbel

RP.

Thrombogenesis or thrombogenic risk?

J Lab Clin Med. 2001;137(6):381–382.

12.

Bertina

Koeleman

Koster

. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–67.

13.

Poort

Rosendaal

Reitsma

Bertina

RM.

A common genetic variation in the 30-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698–3703.

14.

Hanson

Aras

Yang

Tsai

MY.

C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem. 2001;47(4):661–666.

15.

Zimmerman

Ware

RE.

Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol. 1998;59(4):267–272.

16.

Andrade

Annichino-Bizzacchi

Saad

Costa

Arruda

VR.

Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hematol. 1998;59(1):46–50.

17.

Glueck

Freiberg

Tracy

Stroop

Wang

Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Clin Orthop. 1997;334:43–56.

18.

Clarke

Daly

Robinson

. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149–1155.

19.

Frosst

Blom

Milos

. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet. 1995;10(1):111–113.

20.

Margaglione

Colaizzo

Cappucci

. Genetic polymorphism of 5,10-MTHFR reductase gene in offspring of patients with coronary infarction. Thromb Haemostasis. 1999;82(1):19–23.

21.

Kutlar

Holley

McKie

Woods

Kutlar

Frequency of a common thermolabile MTHFR (5,10-methylenetetrahydrofolate reductase) mutant among patients with sickle cell disease. Blood. 1997;90(10 suppl 1):28b.

22.

Kutlar

Tural

Park

Markkowitz

Woods

Kutlar

MTHFR (5,10-methylenetetrahydrofolare reductase) 677 C-T mutation as a candidate risk factor for avascular necrosis (AVN) in patients with sickle cell disease. Blood. 1998;82(10 suppl 1):695a.

23.

Fawaz

Bashawery

Al-Sheikh

Qatari

Al-Othman

Almawi

WY.

Factor V-Leiden, Prothrombin G20210A, and MTHFR C677T mutations among patients with sickle cell disease in Eastern Saudi Arabia. Am J Hematol. 2004;76(3):307–309.

24.

Al-Jaouni

SK.

Primary thrombophilia in Saudi Arabia. Saudi Med J. 2003;24(6):614–616.

25.

Belhassen

Pelle

Sediame

. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood. 2001;97(6):1584–1589.

26.

Cumming

Olujohungbe

Keeney

Singh

Hay

Serjeant

GR.

The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol. 1999;107(3):569–571.

27.

Balasa

Kalinyak

Bean

Stroop

Gruppo

RA.

Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 2002;24(5):374–379.

28.

Romana

Muralitharan

Ramasawmy

Nagel

Krishnamoorthy

Thrombosis-associated gene variants in sickle cell anemia. Thromb Haemost. 2002;87(2):356–358.

29.

Koch

Nabel

Junker

. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr. 1999;158(suppl 3):S113–S116.

30.

Brown

Luddington

Baglin

Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor VLeiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998;103(1):42–44.

31.

Alhenc-Gelas

Arnaud

Nicaud

. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost. 1999;81(4):506–510.

32.

Kluijtmans

den Heijer

Reitsma

Heil

Blom

Rosendaal

FR.

Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost. 1998;79(2):254–258.

33.

Margaglione

D’Andrea

d’Addedda

. The methylenetetrahydrofolate reductase TT677genotype is associated with venous thrombosis independently ofthe coexistence of the FV Leiden and the prothrombin A20210mutation. Thromb Haemost. 1998;79(5):907–911.

34.

Salomon

Steinberg

Zivelin

. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19(3):511–518.

35.

Morelli

Lourenço

D’Almeida

. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. Blood Coagul Fibrinolysis. 2002;13:271–275.

36.

Franco

Reitsma

Lourenço

. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost. 1999;81(5):676–679.

37.

Neto

Lourenço

Noguiti

MAE

. The clinical impact of MTHFR polymorphisms on the vascular complications of sicklecell disease. Braz Med Biol Res. 2006;39(10):1291–1295.

38.

Couto

Vilas Boas

Lyra

. AC677T methylenetetrahydrofolate reductase (MTHFR)polymorphisms and G20210A mutation in the prothrombin gene of sickle cell anemia patients from Northeast Brazil. Hemoglobin. 2004;28(3):237–241.

39.

Franco

Araujo

Guerreiro

Elion

Zago

MA.

Analysis of the 677 C®T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemostasis. 1998;79(1):119–121.